ADMA Biologics, Inc. (ADMA) stock
ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 16/3036% below fair value
$13.68+0.44 (+3.32%)
Close on Nov 13, 2026Market cap $3.06BP/E 17.8Yield –
ADMA Biologics r&d expenses
Research and development expenses are spending on new products and technology.
ADMA Biologics's R&D Expenses for the twelve months ending Sep 30, 2026 was $14.48M, up 283.4% year over year. For fiscal 2025 it was $4.76M, up 162.7% from the year before. Over ten years it grew -3.8% a year on average. The highest annual figure on record is $9.52M in fiscal 2014.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.76M | +162.7% |
| FY2024 | Dec 31, 2024 | $1.81M | -45.1% |
| FY2023 | Dec 31, 2023 | $3.30M | -8.7% |
| FY2022 | Dec 31, 2022 | $3.61M | -0.9% |
| FY2021 | Dec 31, 2021 | $3.65M | -38.3% |
| FY2020 | Dec 31, 2020 | $5.91M | +152.0% |
| FY2019 | Dec 31, 2019 | $2.34M | -40.3% |
| FY2018 | Dec 31, 2018 | $3.93M | -29.5% |
| FY2017 | Dec 31, 2017 | $5.57M | -27.6% |
| FY2016 | Dec 31, 2016 | $7.69M | +9.6% |
| FY2015 | Dec 31, 2015 | $7.02M | -26.3% |
| FY2014 | Dec 31, 2014 | $9.52M | +2.3% |
| FY2013 | Dec 31, 2013 | $9.30M | +168.2% |
| FY2012 | Dec 31, 2012 | $3.47M | +436.4% |
| FY2011 | Dec 31, 2011 | $646.76K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $4.49M | +193.8% |
| Q2 FY2026 | Jun 30, 2026 | $6.01M | +483.3% |
| Q1 FY2026 | Mar 31, 2026 | $2.60M | +214.4% |
| Q4 FY2025 | Dec 31, 2025 | $1.38M | +251.9% |
| Q3 FY2025 | Sep 30, 2025 | $1.53M | +270.9% |
| Q2 FY2025 | Jun 30, 2025 | $1.03M | +84.1% |
| Q1 FY2025 | Mar 31, 2025 | $826.00K | +83.6% |
| Q4 FY2024 | Dec 31, 2024 | $391.00K | -12.3% |
| Q3 FY2024 | Sep 30, 2024 | $412.00K | -30.9% |
| Q2 FY2024 | Jun 30, 2024 | $560.00K | -60.1% |
| Q1 FY2024 | Mar 31, 2024 | $450.00K | -47.4% |
| Q4 FY2023 | Dec 31, 2023 | $446.00K | -58.5% |
| Q3 FY2023 | Sep 30, 2023 | $596.00K | -42.8% |
| Q2 FY2023 | Jun 30, 2023 | $1.40M | +60.6% |
| Q1 FY2023 | Mar 31, 2023 | $855.00K | +37.0% |
| Q4 FY2022 | Dec 31, 2022 | $1.07M | +47.4% |
| Q3 FY2022 | Sep 30, 2022 | $1.04M | +35.2% |
| Q2 FY2022 | Jun 30, 2022 | $873.39K | -24.6% |
| Q1 FY2022 | Mar 31, 2022 | $624.11K | -36.8% |
| Q4 FY2021 | Dec 31, 2021 | $728.93K | -28.1% |
| Q3 FY2021 | Sep 30, 2021 | $770.56K | -54.9% |
| Q2 FY2021 | Jun 30, 2021 | $1.16M | -30.0% |
| Q1 FY2021 | Mar 31, 2021 | $987.65K | -35.4% |
| Q4 FY2020 | Dec 31, 2020 | $1.01M | +118.0% |
| Q3 FY2020 | Sep 30, 2020 | $1.71M | +247.7% |
| Q2 FY2020 | Jun 30, 2020 | $1.66M | +220.4% |
| Q1 FY2020 | Mar 31, 2020 | $1.53M | +75.6% |
| Q4 FY2019 | Dec 31, 2019 | $464.82K | -49.3% |
| Q3 FY2019 | Sep 30, 2019 | $491.40K | -51.0% |
| Q2 FY2019 | Jun 30, 2019 | $516.99K | -50.3% |
| Q1 FY2019 | Mar 31, 2019 | $870.64K | -9.8% |
| Q4 FY2018 | Dec 31, 2018 | $917.30K | -23.9% |
| Q3 FY2018 | Sep 30, 2018 | $1.00M | -44.7% |
| Q2 FY2018 | Jun 30, 2018 | $1.04M | -23.4% |
| Q1 FY2018 | Mar 31, 2018 | $965.57K | -19.0% |
| Q4 FY2017 | Dec 31, 2017 | $1.20M | +106.5% |
| Q3 FY2017 | Sep 30, 2017 | $1.81M | – |
| Q2 FY2017 | Jun 30, 2017 | $1.36M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.19M | – |
| Q4 FY2016 | Dec 31, 2016 | $583.37K | – |
See a number that looks wrong?